PMC:7073332 / 14099-14735 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"345","span":{"begin":43,"end":47},"obj":"Species"},{"id":"350","span":{"begin":543,"end":548},"obj":"Species"},{"id":"351","span":{"begin":98,"end":102},"obj":"Species"},{"id":"352","span":{"begin":152,"end":156},"obj":"Species"},{"id":"353","span":{"begin":611,"end":615},"obj":"Species"}],"attributes":[{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"Tax:694448"},{"id":"A350","pred":"tao:has_database_id","subj":"350","obj":"Tax:9606"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"Tax:694448"},{"id":"A352","pred":"tao:has_database_id","subj":"352","obj":"Tax:694448"},{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"Tax:694448"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Fig. 3 Drug-target network analysis of the HCoV–host interactome.\na A subnetwork highlighting the HCoV–host interactome. Nodes represent three types of HCoV-associated host proteins: targetgable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins do not have any known ligands), neighbors (protein–protein interaction partners). Edge colors indicate five types of experimental evidence of the protein–protein interactions (see Materials and methods). 3D three-dimensional structure. b, c KEGG human pathway (b) and gene ontology enrichment analyses (c) for the HCoV-associated proteins."}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T67","span":{"begin":173,"end":181},"obj":"Body_part"},{"id":"T68","span":{"begin":196,"end":204},"obj":"Body_part"},{"id":"T69","span":{"begin":288,"end":296},"obj":"Body_part"},{"id":"T70","span":{"begin":340,"end":347},"obj":"Body_part"},{"id":"T71","span":{"begin":348,"end":355},"obj":"Body_part"},{"id":"T72","span":{"begin":443,"end":450},"obj":"Body_part"},{"id":"T73","span":{"begin":451,"end":458},"obj":"Body_part"},{"id":"T74","span":{"begin":565,"end":569},"obj":"Body_part"},{"id":"T75","span":{"begin":627,"end":635},"obj":"Body_part"}],"attributes":[{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A69","pred":"fma_id","subj":"T69","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Fig. 3 Drug-target network analysis of the HCoV–host interactome.\na A subnetwork highlighting the HCoV–host interactome. Nodes represent three types of HCoV-associated host proteins: targetgable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins do not have any known ligands), neighbors (protein–protein interaction partners). Edge colors indicate five types of experimental evidence of the protein–protein interactions (see Materials and methods). 3D three-dimensional structure. b, c KEGG human pathway (b) and gene ontology enrichment analyses (c) for the HCoV-associated proteins."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T94","span":{"begin":66,"end":69},"obj":"http://purl.obolibrary.org/obo/CLO_0001627"},{"id":"T95","span":{"begin":533,"end":534},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T96","span":{"begin":543,"end":548},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T97","span":{"begin":558,"end":559},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T98","span":{"begin":565,"end":569},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"}],"text":"Fig. 3 Drug-target network analysis of the HCoV–host interactome.\na A subnetwork highlighting the HCoV–host interactome. Nodes represent three types of HCoV-associated host proteins: targetgable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins do not have any known ligands), neighbors (protein–protein interaction partners). Edge colors indicate five types of experimental evidence of the protein–protein interactions (see Materials and methods). 3D three-dimensional structure. b, c KEGG human pathway (b) and gene ontology enrichment analyses (c) for the HCoV-associated proteins."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T131","span":{"begin":173,"end":181},"obj":"Chemical"},{"id":"T132","span":{"begin":196,"end":204},"obj":"Chemical"},{"id":"T133","span":{"begin":233,"end":238},"obj":"Chemical"},{"id":"T134","span":{"begin":242,"end":247},"obj":"Chemical"},{"id":"T135","span":{"begin":288,"end":296},"obj":"Chemical"},{"id":"T136","span":{"begin":319,"end":326},"obj":"Chemical"},{"id":"T137","span":{"begin":340,"end":347},"obj":"Chemical"},{"id":"T138","span":{"begin":348,"end":355},"obj":"Chemical"},{"id":"T139","span":{"begin":443,"end":450},"obj":"Chemical"},{"id":"T140","span":{"begin":451,"end":458},"obj":"Chemical"},{"id":"T141","span":{"begin":627,"end":635},"obj":"Chemical"}],"attributes":[{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A136","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A137","pred":"chebi_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A138","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A141","pred":"chebi_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Fig. 3 Drug-target network analysis of the HCoV–host interactome.\na A subnetwork highlighting the HCoV–host interactome. Nodes represent three types of HCoV-associated host proteins: targetgable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins do not have any known ligands), neighbors (protein–protein interaction partners). Edge colors indicate five types of experimental evidence of the protein–protein interactions (see Materials and methods). 3D three-dimensional structure. b, c KEGG human pathway (b) and gene ontology enrichment analyses (c) for the HCoV-associated proteins."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T86","span":{"begin":0,"end":65},"obj":"Sentence"},{"id":"T87","span":{"begin":66,"end":120},"obj":"Sentence"},{"id":"T88","span":{"begin":121,"end":378},"obj":"Sentence"},{"id":"T89","span":{"begin":379,"end":500},"obj":"Sentence"},{"id":"T90","span":{"begin":501,"end":636},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fig. 3 Drug-target network analysis of the HCoV–host interactome.\na A subnetwork highlighting the HCoV–host interactome. Nodes represent three types of HCoV-associated host proteins: targetgable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins do not have any known ligands), neighbors (protein–protein interaction partners). Edge colors indicate five types of experimental evidence of the protein–protein interactions (see Materials and methods). 3D three-dimensional structure. b, c KEGG human pathway (b) and gene ontology enrichment analyses (c) for the HCoV-associated proteins."}